Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
Condition: Hemophilia A Intervention: Drug: Damoctocog alfa pegol (Jivi, BAY94-9027) Sponsor: Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bleeding | Haemophilia | Hemophilia | Learning | Research | Study | Universities & Medical Training